CV Sciences Q3 2021 revenue down 8% to $5.1M; cash drops to $1.7M

CV Sciences, Inc.

2021-Q3 EPS reported -$0.06 revenue$15,079,000

Revenue $5.1M vs $5.6M YoY (-8%); operating loss $3.0M vs $3.2M.
Gross margin 46.2% (up 200 bps); retail stores 7,700 (up from 6,200).
Cash balance $1.7M at quarter-end vs $4.5M at year-end.
PPP loan of $2.9M forgiven; launched PlusCBD Reserve line.
CEO cites CA AB 45 passage as favorable regulatory momentum for 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.